Literature DB >> 30703198

Patient Experience of Thyroid Cancer Active Surveillance in Japan.

Louise Davies1,2,3, Benjamin R Roman4, Mitsuhiro Fukushima5, Yasuhiro Ito5, Akira Miyauchi5.   

Abstract

Importance: The burden of concern for patients with thyroid cancer who undergo surgical intervention with or without radioactive iodine is known to be substantial. For patients under active surveillance, this aspect of the patient experience has not been described to date and could be a potential barrier to broader acceptance of surveillance as a cancer management strategy. Objective: To describe the experiences of patients in the longest-standing and largest thyroid cancer active surveillance program. Design, Setting, and Participants: This study used a mixed method of survey, semistructured interviews, and field observation and was conducted at Kuma Hospital in Kobe, Japan. The survey was administered from September 4, 2017, through October 18, 2017, and the field observation was conducted from August 28, 2017, to October 20, 2017. Survey participants were a consecutive sample of 249 patients under active surveillance who were attending the hospital for a surveillance visit, and the semistructured interviewees were a subset of 21 patients. The English-language survey instrument was translated by native Japanese speakers, back-translated into English, and then further refined by a panel of Japanese speakers with expertise in health research. Main Outcomes and Measures: Survey and interview responses and field observations.
Results: In total, 249 surveys were distributed to patients with thyroid cancer on active surveillance. Two hundred forty-three patients (97.6%) completed the survey. Among the respondents, 195 (80.2%) were female and 20 (8.2%) were male (28 [11.5%] responses were missing). Among the subset of 21 patients who participated in the semistructured interview, 3 were male (14.3%), and the mean (range) age was 64 (32-85) years. Thirty-seven percent rated the frequency of cancer worry as occurring sometimes or more. Thirty-two percent said their worry affected their mood somewhat or a lot. Fourteen percent reported that their worry affected their ability to carry out daily activities somewhat or a lot. Cancer spread, later need for surgical intervention, and difficulty with interpreting bodily experiences in the general location of the cancer were among the main sources of worry. Most respondents (60.0%) said their worry was less than it was when they first found out about their cancer. By 3 years after diagnosis, the proportion of participants who reported they were not at all worried increased from 14% (95% CI, 12%-16%) to 25% (95% CI, 23%-26%). Eighty percent (95% CI, 79%-81%) of respondents agreed or strongly agreed that their decision to do active surveillance matched their personal values, and 83% (95% CI, 82%-84%) agreed or strongly agreed that choosing active surveillance was the best decision for them personally. Most patients (77%) had not heard of active surveillance before they were offered the option. Conclusions and Relevance: Cancer concern was common among patients with thyroid cancer under active surveillance, which is comparable to the worry among actively treated patients. Levels of cancer worry reported by patients under active surveillance decreased over time, and patients expressed satisfaction with their disease management decision. These findings suggest that the possibility of cancer worry should not be viewed as prohibitive to successful active surveillance in thyroid cancer.

Entities:  

Mesh:

Year:  2019        PMID: 30703198      PMCID: PMC6481594          DOI: 10.1001/jamaoto.2018.4131

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  41 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE.

Authors:  Hossein Gharib; Enrico Papini; Jeffrey R Garber; Daniel S Duick; R Mack Harrell; Laszlo Hegedüs; Ralf Paschke; Roberto Valcavi; Paolo Vitti
Journal:  Endocr Pract       Date:  2016-05       Impact factor: 3.443

3.  The Control Preferences Scale.

Authors:  L F Degner; J A Sloan; P Venkatesh
Journal:  Can J Nurs Res       Date:  1997

4.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Authors:  Richard Choo; Laurence Klotz; Cyril Danjoux; Gerard C Morton; Gerrit DeBoer; Ewa Szumacher; Neil Fleshner; Peter Bunting; George Hruby
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy.

Authors:  W C Black; H G Welch
Journal:  N Engl J Med       Date:  1993-04-29       Impact factor: 91.245

6.  Unrealistic optimism about susceptibility to health problems.

Authors:  N D Weinstein
Journal:  J Behav Med       Date:  1982-12

7.  Patient satisfaction with health care decisions: the satisfaction with decision scale.

Authors:  M Holmes-Rovner; J Kroll; N Schmitt; D R Rovner; M L Breer; M L Rothert; G Padonu; G Talarczyk
Journal:  Med Decis Making       Date:  1996 Jan-Mar       Impact factor: 2.583

8.  The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries.

Authors:  Salvatore Vaccarella; Luigino Dal Maso; Mathieu Laversanne; Freddie Bray; Martyn Plummer; Silvia Franceschi
Journal:  Thyroid       Date:  2015-08-20       Impact factor: 6.568

Review 9.  Thyroid nodules and cancer management guidelines: comparisons and controversies.

Authors:  Fadi Nabhan; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2016-12-13       Impact factor: 5.678

10.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Authors:  J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

View more
  21 in total

1.  Nonsurgical Thermal Ablation of Thyroid Nodules: Not if, but Why, When, and How?

Authors:  Laszlo Hegedüs; Akira Miyauchi; R Michael Tuttle
Journal:  Thyroid       Date:  2020-09-07       Impact factor: 6.568

Review 2.  Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand?

Authors:  Min Ji Jeon; Won Gu Kim; Ki-Wook Chung; Jung Hwan Baek; Won Bae Kim; Young Kee Shong
Journal:  Eur Thyroid J       Date:  2019-09-25

3.  Peace of Mind: A Role in Unnecessary Care?

Authors:  Michelle M Chen; Tasha M Hughes; Lesly A Dossett; Susan C Pitt
Journal:  J Clin Oncol       Date:  2021-12-09       Impact factor: 44.544

4.  Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma.

Authors:  X Wei; Y Min; Y Feng; D He; X Zeng; Y Huang; S Fan; H Chen; J Chen; K Xiang; H Luo; G Yin; D Hu
Journal:  J Endocrinol Invest       Date:  2021-09-07       Impact factor: 4.256

5.  The Influence of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A Qualitative Study.

Authors:  Susan C Pitt; Megan C Saucke; Benjamin R Roman; Stewart C Alexander; Corrine I Voils
Journal:  Thyroid       Date:  2021-11-26       Impact factor: 6.568

6.  A Mathematical Model to Assess the Effect of Residual Positive Lymph Nodes on the Survival of Patients With Papillary Thyroid Microcarcinoma.

Authors:  Wen Liu; Xuejing Yan; Zhizhong Dong; Yanjun Su; Yunhai Ma; Jianming Zhang; Chang Diao; Jun Qian; Tao Ran; Ruochuan Cheng
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 7.  Updates on the Management of Thyroid Cancer.

Authors:  Katherine A Araque; Sriram Gubbi; Joanna Klubo-Gwiezdzinska
Journal:  Horm Metab Res       Date:  2020-02-10       Impact factor: 2.936

8.  Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center.

Authors:  Eleonora Molinaro; Maria Cristina Campopiano; Letizia Pieruzzi; Antonio Matrone; Laura Agate; Valeria Bottici; David Viola; Virginia Cappagli; Laura Valerio; Carlotta Giani; Luciana Puleo; Loredana Lorusso; Paolo Piaggi; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; R Michael Tuttle; Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

9.  Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey.

Authors:  Susan C Pitt; Nan Yang; Megan C Saucke; Nicholas Marka; Bret Hanlon; Kristin L Long; Alexandria D McDow; J P Brito; Benjamin R Roman
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

10.  NATIONAL SURVEY OF ENDOCRINOLOGISTS AND SURGEONS REGARDING ACTIVE SURVEILLANCE FOR LOW-RISK PAPILLARY THYROID CANCER.

Authors:  Benjamin R Roman; Juan P Brito; Megan C Saucke; Shivangi Lohia; Catherine B Jensen; Nick Zaborek; Jamia Linn Jennings; Robert M Tuttle; Louise Davies; Susan C Pitt
Journal:  Endocr Pract       Date:  2020-11-17       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.